These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 30788495)
1. The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count. Khieu ML; Broadwater DR; Aden JK; Coviello JM; Lynch DT; Hall JM Am J Clin Pathol; 2019 May; 151(6):542-550. PubMed ID: 30788495 [TBL] [Abstract][Full Text] [Related]
2. Mitotic Index Determined by Phosphohistone H3 Immunohistochemistry for Precise Grading in Follicular Lymphoma. Bedekovics J; Irsai G; Hegyi K; Beke L; Krenács L; Gergely L; Méhes G Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):579-585. PubMed ID: 27997502 [TBL] [Abstract][Full Text] [Related]
3. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas. Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284 [TBL] [Abstract][Full Text] [Related]
4. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds. Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026 [TBL] [Abstract][Full Text] [Related]
5. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors. Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845 [TBL] [Abstract][Full Text] [Related]
6. Interobserver variability of mitotic index and utility of PHH3 for risk stratification in gastrointestinal stromal tumors. Alkhasawneh A; Reith JD; Toro TZ; Ayed AO; Lu X; George TJ; Duckworth LV Am J Clin Pathol; 2015 Mar; 143(3):385-92. PubMed ID: 25696796 [TBL] [Abstract][Full Text] [Related]
7. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody. Medani H; Elshiekh M; Naresh KN J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701 [TBL] [Abstract][Full Text] [Related]
8. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies. Puripat N; Loharamtaweethong K Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302 [TBL] [Abstract][Full Text] [Related]
9. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer. van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844 [TBL] [Abstract][Full Text] [Related]
10. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III. Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054 [TBL] [Abstract][Full Text] [Related]
11. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. Ladstein RG; Bachmann IM; Straume O; Akslen LA BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247 [TBL] [Abstract][Full Text] [Related]
12. The Utility of Phosphohistone H3 in Inter-Observer Variability of Mitotic Count in Meningioma, is There Any Benefit? Saffar H; Okhovat H; Arbabsoleymani S; Tavangar SM; Khoshnevisan A; Hajinasrollah G; Hamidi Afra Z; Saffar H Asian Pac J Cancer Prev; 2021 Jul; 22(7):2049-2052. PubMed ID: 34319026 [TBL] [Abstract][Full Text] [Related]
13. The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens. Draganova-Tacheva R; Bibbo M; Birbe R; Daskalakis C; Solomides C Acta Cytol; 2013; 57(3):291-5. PubMed ID: 23635399 [TBL] [Abstract][Full Text] [Related]
14. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast. Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415 [TBL] [Abstract][Full Text] [Related]
15. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa. Gunia S; Kakies C; Erbersdobler A; Koch S; May M J Clin Pathol; 2012 Aug; 65(8):715-20. PubMed ID: 22554964 [TBL] [Abstract][Full Text] [Related]
16. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3. Tracht J; Zhang K; Peker D J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471 [TBL] [Abstract][Full Text] [Related]
17. Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm). Idriss MH; Kazlouskaya V; Malhotra S; Andres C; Elston DM J Cutan Pathol; 2013 Jun; 40(6):557-63. PubMed ID: 23550775 [TBL] [Abstract][Full Text] [Related]
18. [Cut-off value of Ki-67 labeling index in the pathologic grading of follicular lymphoma]. Hou WH; Duan XK; Wei P; Xie JL; Zheng YY; Zhang YL; Zhou XG Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):696-699. PubMed ID: 30220124 [No Abstract] [Full Text] [Related]
19. The Utility of Phosphohistone H3 in Breast Cancer Grading. Cui X; Harada S; Shen D; Siegal GP; Wei S Appl Immunohistochem Mol Morphol; 2015; 23(10):689-95. PubMed ID: 25611243 [TBL] [Abstract][Full Text] [Related]
20. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]